TCTC Holdings LLC Has $2.11 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

TCTC Holdings LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,727 shares of the company’s stock after buying an additional 62 shares during the period. TCTC Holdings LLC’s holdings in Eli Lilly and Company were worth $2,105,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pitti Group Wealth Management LLC increased its holdings in Eli Lilly and Company by 3.0% during the 4th quarter. Pitti Group Wealth Management LLC now owns 1,708 shares of the company’s stock worth $1,319,000 after purchasing an additional 49 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Eli Lilly and Company by 11.1% in the fourth quarter. Parallel Advisors LLC now owns 26,277 shares of the company’s stock valued at $20,286,000 after acquiring an additional 2,628 shares in the last quarter. Cibc World Markets Corp grew its holdings in shares of Eli Lilly and Company by 15.7% in the fourth quarter. Cibc World Markets Corp now owns 125,207 shares of the company’s stock valued at $96,660,000 after acquiring an additional 17,022 shares in the last quarter. Polen Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 164.4% in the fourth quarter. Polen Capital Management LLC now owns 1,295,389 shares of the company’s stock valued at $1,000,040,000 after acquiring an additional 805,434 shares in the last quarter. Finally, SlateStone Wealth LLC grew its holdings in shares of Eli Lilly and Company by 4.2% in the fourth quarter. SlateStone Wealth LLC now owns 3,275 shares of the company’s stock valued at $2,528,000 after acquiring an additional 131 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 1.5 %

Shares of NYSE:LLY opened at $813.55 on Monday. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The company has a market cap of $771.38 billion, a PE ratio of 69.47, a P/E/G ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock’s 50-day moving average is $830.81 and its 200 day moving average is $842.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has authorized a stock buyback plan on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a research report on Thursday, March 6th. Finally, Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.